Enjoy complimentary customisation on priority with our Enterprise License!
The pregabalin market share is expected to increase by USD 153.03 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 3.74%.
This pregabalin market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers pregabalin market segmentations by application (neuropathic pain, epilepsy, anxiety disorders, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The pregabalin market report also offers information on several market vendors, including Biomax Biotechnics Pvt. Ltd., Camber Pharmaceuticals Inc., Cipla Ltd., Dr. Kumars Pharmaceuticals, Genesis Biotec Inc., H. L. Healthcare Pvt. Ltd., Lupin Ltd, Medley Pharmaceuticals Ltd., MK Medicine, MSN Laboratories, Neuracle Lifesciences Pvt. Ltd., Novartis AG, Pfizer Inc., Phoenix Biologicals Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Swastik Life Sciences, Torrent Pharmaceuticals Ltd., and Vibcare Pharma Pvt. Ltd. among others.
Download Report Sample to Unlock the Pregabalin Market Size for the Forecast Period and Other Important Statistics
The presence of a large patient pool related to neuropathic pain is notably driving the pregabalin market growth, although factors such as growing preference for alternatives may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the pregabalin industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Pregabalin Market Driver
The presence of a large patient pool related to neuropathic pain is one of the key drivers supporting the pregabalin market growth. Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disk. There have been growing cases of these disorders, especially in the geriatric population. Meanwhile, the increasing number of individuals preferring chemotherapy for cancer treatment is fueling cases of chemotherapy-induced pain. Furthermore, according to the CDC, the incidence of shingles is approximately four per 1,000 US population annually. Overall, there are an estimated one million cases of herpes zoster in the US annually. Such a scenario will lead to an increase in the adoption of pregabalin, which, in turn, will drive the growth of the market during the forecast period.
Key Pregabalin Market Trend
Growing focus on emerging economies is one of the key pregabalin market trends contributing to the market growth. The increasing incidence of individuals with various diseases such as neuropathic pain, epilepsy, anxiety disorders, and fibromyalgia has fueled the demand for pregabalin in regions such as China, India, and Brazil. In addition, the research institutes have issued guidelines to address the unmet needs in the treatment of such incidences. Moreover, vendors are also looking to tap the potential in emerging economies. For instance, Pfizer, Cipla, and Lupin are some of the companies that are increasingly conducting R&D activities to develop effective treatments in APAC. Such initiatives are expected to positively impact the growth of the global pregabalin market during the forecast period.
Key Pregabalin Market Challenge
Growing preference for alternatives is one of the key factors hindering the pregabalin market growth. As the current treatments are associated with many unmet needs, end-users are looking to shift to alternative therapies. For instance, diabetic neuropathic pain can be reduced by supplementing essential acids, alpha-lipoic acid, gamma-linolenic acid, and omega-3 fatty acids. Similarly, acupuncture can be an effective way to manage peripheral neuropathy. Acupuncture uses pressure points across the body to realign the body's energy. Thus, the use of these alternative therapies may hinder growth prospects in the forecast period.
This pregabalin market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global pregabalin market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the pregabalin market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the pregabalin market encompasses successful business strategies deployed by the key vendors. The pregabalin market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The pregabalin market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.
Our report provides extensive information on the value chain analysis for the pregabalin market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
36% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the pregabalin market in North America. Market growth in this region will be faster than the growth of the market in Europe.
The increase in the older population, coupled with the established adoption of LYRICA and Cymbalta in new indications and the introduction of new drugs for the treatment of neuropathic pain, will facilitate the pregabalin market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 negatively impacted the regional market. However, the initiation of large-scale COVID-19 vaccination drives by the government in Q4 2020 led to a decrease in the number of COVID-19 cases in the region. This has resulted in the resumption of operations in healthcare facilities, which has increased the manufacturing of pregabalin in North America.
To gain further insights on the market contribution of various segments Request PDF Sample
The pregabalin market share growth in the neuropathic pain segment will be significant during the forecast period. Neuropathic pain affects 20% to 30% of diabetic neuropathy patients. Thus, the demand for pregabalin is rising due to more occurrences of diabetic neuropathy, which is boosting the growth of the market. Pregabalin is an alternative treatment for people with neuropathic pain that has not responded to other drugs. It effectively reduces the symptoms of numerous neuropathic pain conditions and positions itself as a first-line therapy option with exceptional safety and efficacy. These factors will drive segment growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the pregabalin market size and actionable market insights on the post-COVID-19 impact on each segment.
Pregabalin Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.74% |
Market growth 2022-2026 |
$153.03 million |
Market structure |
Fragmented |
YoY growth (%) |
3.27 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key consumer countries |
US, Canada, Germany, China, Japan, and Republic of Korea |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Biomax Biotechnics Pvt. Ltd., Camber Pharmaceuticals Inc., Cipla Ltd., Dr. Kumars Pharmaceuticals, Genesis Biotec Inc., H. L. Healthcare Pvt. Ltd., Lupin Ltd, Medley Pharmaceuticals Ltd., MK Medicine, MSN Laboratories, Neuracle Lifesciences Pvt. Ltd., Novartis AG, Pfizer Inc., Phoenix Biologicals Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Swastik Life Sciences, Torrent Pharmaceuticals Ltd., and Vibcare Pharma Pvt. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.